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Carbapenem resistanceTwo new examples of OXA-72–producing Acinetobacter baumannii isolate resistant to a broad spectrum of
antimicrobials, but not polymyxin B, have been identiﬁed in Recife, Brazil. Molecular typing indicated a close
genetic link with the OXA-72–producing A. baumannii previously isolated in São Paulo, suggesting the
possibility of clonal dissemination within the country.2696; fax: +55-81-3453-1911.
Sá Cavalcanti).
l rights reserved.© 2013 Elsevier Inc. All rights reserved.Infections caused by multidrug-resistant Acinetobacter baumannii
are extremely difﬁcult to treat. Acquired carbapenem resistance in
A. baumannii is frequently associated with Ambler class D carbapene-
mase production such as OXA-23, OXA-24, OXA-51, OXA-58, and OXA-
143 groups or clusters (Zavascki et al., 2010). The intrinsic blaOXA-51
gene is characteristic of this species and is usually weakly expressed
(Zavascki et al., 2010). However, it can play a role in carbapenem
resistance when an ISAba1 precedes the gene, providing promoter
sequences that increase its expression (Werneck et al., 2011).
Outbreaks of OXA-producing A. baumannii have occurred through-
out the world, including Brazil. However, these reports are restricted
to the south and southeastern regions of the country, and until now,
there have been no reported cases of the occurrence of this phenotype
in the north east (Zavascki et al., 2010).
From a total of 228 A. baumannii isolates recovered from different
patients admitted to 2 teaching hospitals in Recife, Brazil, from
January 2010 to November 2011, 2 isolates that tested positive in the
modiﬁed Hodge test and which had a XDR (extensively drug
resistant) phenotype were selected. The ﬁrst isolate (Ac 041) came
from a tracheal aspirate sample taken from a 46-year-old man who
had an AIDS diagnosis in 2010. The second isolate (Ac 928) came from
a uroculture of a 60-year-old hypertensive, diabetic man with renal
insufﬁciency and who had had a heart attack episode in 2011.
Bacterial identiﬁcation was carried out in accordance with standard
biochemical tests and conﬁrmed by means of the automated MiniAPI® System ID 32 E (bioMérieux, Marcy-l’Étoile, France). Suscepti-
bility testing was performed by disk diffusion, Etest®, and the broth
microdilution method, according to CLSI (2012) guidelines.
The isolates were screened for metallo-β-lactamase (MBL)
production by the disk approximation test with 2-mercaptopropionic
acid. The resulting phenotype from theMBL test was negative for both
isolates. PCRs targeting blaSPM-1, blaIMP, and blaVIM genes were carried
out as previously described (Cavalcanti et al., 2012). None of the
isolates showed ampliﬁcation for MBL genes. A multiplex PCR assay
targeting carbapenem-hydrolysing class D β-lactamase–encoding
genes was performed (Higgins et al., 2010). The presence and position
of ISAba1 and the presence of class 1 and 2 integrons were also
investigated. The amplicons were puriﬁed with the aid of a PCR
puriﬁcation kit (Invitrogen, Carlsbad, CA, USA) and submitted for DNA
sequencing. The nucleotide sequences were evaluated using BioEdit™
software (Ibis Biosciences, Carlsbad, USA) and submitted for online
BLASTn analysis at Genebank (NCBI).
PCR experiment resulted in a 246-bp amplicon in both isolates that
showed 100% identity with the blaOXA-72 gene sequence deposited in
the GenBank database. Plasmid extraction of the Ac 041 and Ac 928
isolates, followed by electrophoresis and subsequent PCR, showed
that the blaOXA-72 was located in plasmids of ~44 kb and ~11 kb,
respectively (Table 1). Ampliﬁcation product for the blaOXA-51-like
gene was also obtained. The PCR with combined primers targeting the
blaOXA-51-like or blaOXA-24-like and the insertion sequence ISAba1
(ISAba1 forward/OXA-51-like reverse and ISAba1 forward/OXA-24-
like reverse) showed negative results (Table 1), indicating that the
expression of these genes was not driven by the promoter present in
this insertion sequence element.
Table 1











Ac 041 neg blaOXA-51/
blaOXA-72
intI1/intI2 + neg neg
Ac 928 neg blaOXA-51/
blaOXA-72
intI2 + neg neg
Strain IPMa MEMa CAZa ATMa PMBa CIPb TZPb GENb
Ac 041 8 N32 N256 N64 0.38 N8 128 32
Ac 928 N32 N32 N256 96 0.19 N8 256 8
ATM = aztreonam; CAZ = ceftazidime; CIP = ciproﬂoxacin; GEN = gentamicin;
IPM = imipenem; MEM = meropenem; PMB = polymyxin B; TZP = piperacilin/
tazobactam; neg = negative; + = positive.
a Antimicrobial susceptibility testing by Etest®.
b Antimicrobial susceptibility testing by broth microdilution method.
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polymyxin B. This is compatible with an XDR phenotype (Table 1). A
combination of different resistance mechanisms such as efﬂux pump
overexpression, porin loss, penicillin-binding protein modiﬁcation,
and the presence of multiple gene cassettes carried by class 1 and 2
integrons should also be considered as possible factors determining
this phenotype, contributing to its clinical severity (Migliavacca et al.,
2013; Zavascki et al., 2010).Fig. 1. PFGE of SmaI-digested chromosomal DNA of the OXA-72–producing A.
baumannii isolates. M = lambda ladder PFG Marker (New England Biolabs); lanes 1
and 2 = isolates 041 and 928, respectively; lanes 3 and 4 = isolates from São Paulo
(Werneck et al., 2011; Antonio et al., 2011, respectively). Isolate in lane 4 is
representative of the 2 identical ERIC types detected by the authors.Molecular typing using the pulsed-ﬁeld gel electrophoresis (PFGE)
technique (Fig. 1) revealed that the 2 isolates were indistinguishable
from one another and closely related to 3 interrelated A. baumannii
isolates that harbor the blaOXA-72 gene recently identiﬁed in São Paulo
(Antonio et al., 2011; Werneck et al., 2011). This ﬁnding is indicative
of the beginning of the spread of an epidemic clone across the country,
as happened with the blaSPM-1 in Pseudomonas aeruginosa clone
(Cavalcanti et al., 2012; Zavascki et al., 2010).
The OXA-24–like carbapenemases comprise OXA-40, OXA-25,
OXA-26, and OXA-72 enzymes (Zavascki et al., 2010). The ﬁrst
enzymes of this group were originally described in isolates of A.
baumannii from the Iberian Peninsula and, for a time, were restricted
to Europe and USA, with no reports in Brazil until 2011 (Antonio et al.,
2011; Werneck et al., 2011; Zavascki et al., 2010). OXA-72 was ﬁrst
described in an Acinetobacter isolate from Thailand in 2004 and has
since been reported in a single A. baumannii strain from China and as a
major mechanism of carbapenem resistance in a Taiwanese hospital
(Werneck et al., 2011).
In conclusion, we report 2 cases of OXA-72–producing A.
baumannii with an XDR proﬁle identiﬁed in 2 different hospitals
in Recife, which are strongly related to the isolates identiﬁed in
São Paulo. This observation reinforces the continued importance of
careful epidemiological surveillance and enhanced control mea-
sures in this country. The present work emphasizes the potential
for this gene to spread between different countries and distinct
geographical regions, thus further restricting the therapeutic
options available to patients.
Acknowledgments
The authors thank to Dr Ana Cristina Gales (Laboratório Alerta
and Laboratório Especial de Microbiologia Clínica, Universidade
Federal de São Paulo) and Dr Nilton Lincopan (Departamento de
Microbiologia, Universidade de São Paulo) who kindly provided the
OXA-producing A. baumannii isolates used as reference strains. This
work was supported by the Brazilian Funding Agencies CNPq, CAPES,
and FACEPE.
References
Antonio CS, Neves PR, Medeiros M, Mamizuka EM, Araújo MRE, Lincopan N. High
prevalence of carbapenem-resistant Acinetobacter baumannii carrying the blaOXA-
143 gene in Brazilian hospitals. Antimicrob Agents Chemother 2011;55:1322–3.
Cavalcanti FL, Almeida ACS, Vilela MA, Morais MMC, Morais Junior MA. Changing the
epidemiology of carbapenem-resistant Pseudomonas aeruginosa in a Brazilian
teaching hospital: the replacement of São Paulo metallo-β-lactamase–producing
isolates. Mem Inst Oswaldo Cruz 2012;107:420–3.
Clinical and Laboratory Standards Institute (CLSI). Performance standards for
antimicrobial susceptibility testing; 22th informational supplement (CLSI M100-
S22). Wayne, PA: CLSI; 2012.
Higgins PG, Lehmann M, Seifert H. Inclusion of OXA-143 primers in a multiplex
polymerase chain reaction (PCR) for genes encoding prevalent OXA carbapene-
mases in Acinetobacter spp. Int J Antimicrob Agents 2010;35:305.
Migliavacca R, Espinal P, Principe L, et al. Characterization of resistance mechanisms
and genetic relatedness of carbapenem-resistant Acinetobacter baumannii isolated
from blood, Italy. Diagn Microbiol Infect Dis 2013;75:180–6.
Werneck JS, Picão RC, Carvalhaes CG, Cardoso JP, Gales AC. OXA-72-producing
Acinetobacter baumannii in Brazil: a case report. J Antimicrob Chemother
2011;66:452–4.
Zavascki AP, Carvalhaes CG, Picão RC, Gales AC. Multidrug-resistant Pseudomonas
aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications
for therapy. Expert Rev Anti Infect 2010;8:71–93.
